[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Ozmosi [@OzmosiHealth](/creator/twitter/OzmosiHealth) on x 2629 followers Created: 2025-07-09 11:32:37 UTC $KRYS First patient dosed in Phase 1/2 trial of KB801 for Neurotrophic Keratitis treatment, announces Krystal Biotech. More Info: $XBI $IBB $XPH $PPH  XXX engagements  **Related Topics** [$pph](/topic/$pph) [$xph](/topic/$xph) [$ibb](/topic/$ibb) [$xbi](/topic/$xbi) [more info](/topic/more-info) [$krys](/topic/$krys) [Post Link](https://x.com/OzmosiHealth/status/1942909752713134281)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Ozmosi @OzmosiHealth on x 2629 followers
Created: 2025-07-09 11:32:37 UTC
$KRYS First patient dosed in Phase 1/2 trial of KB801 for Neurotrophic Keratitis treatment, announces Krystal Biotech.
More Info: $XBI $IBB $XPH $PPH
XXX engagements
/post/tweet::1942909752713134281